and CD8
ϩ T lymphocytes, on differentiated T-helper 1 (T h 1) cells, and at lower levels on T h 17 lymphocytes (1), as well as in cells of the innate immune system, including mast cells (2) , macrophages and dendritic cells (DCs) (3), natural killer (NK) and natural killer T (NKT) cells (4) , and monocytes (3) . The expression of this protein is regulated by the T h 1-associated transcription factor T-bet, and reduced Tim-3 levels are seen in T-bet-deficient mice (5) . Tim-3 binds galectin-9 (Gal-9), a member of the S-type lectins whose expression is also regulated by T-bet (6 -9) , which is present in lymphocytes and, according to the local cytokine milieu, in endothelial cells and fibroblasts.
Tim-3 on DCs synergizes with Toll-like receptors to promote TNF-␣ secretion, promoting T h 1-cell responses. Tim-3 is then expressed by T h cells that have differentiated into T h 1, and this favors the T-bet-mediated up-regulation of Gal-9 (2, 5) and the production of IFN␥ (1, 10) . At this point, the engagements of Tim-3 by Gal-9 result in intracellular calcium flux and T h 1-lymphocyte death within a regulatory feedback mechanism (5, 1115); notably, T h 17 lymphocytes are less susceptible to Gal-9-mediated cell death as a consequence of their lower Tim-3 expression levels (1, 10, 16, 17) . Recent results have shown that Gal-9-mediated apoptosis can be prevented by molecular adaptor human leukocyte antigen B (HLA-B)-associated transcript 3 (Bat3), a cellular factor that binds the intracellular tail of Tim-3 and promotes both proliferation and proinflammatory cytokine production (18, 19) .
Tim-3 alterations hamper the apoptosis of antigenspecific T h 1 cells and play a role in chronic autoimmune diseases, including multiple sclerosis (MS) and rheumatoid arthritis (RA) (20, 21) . In MS, in particular, it was shown that Tim-3 expression correlates with IFN␥ and TNF-␣ concentration in the cerebrospinal fluid (CSF) of patients with an active form of disease (4); CSF-derived T-cell clones express lower levels of Tim-3 compared with those of healthy controls (HCs; ref. 20) ; reduced levels of Tim-3 expression in T lymphocytes can be restored by therapy (22) ; and monocytes and microglia from the active border regions of MS lesions express higher levels of Tim-3 than those from the quiescent center of lesions (3) . Additional results showed that Gal-9 is significantly elevated on the astrocytes present in MS lesions compared to the levels seen in normal human central nervous system (CNS) tissue (3) .
In experimental autoimmune encephalitis (EAE), the archetypal animal model of MS, administration of Tim-3 monoclonal antibody (mAb) during the induction phase worsens disease progression and leads to the accumulation of activated macrophages (23) and a significant demyelination of spinal cord neurons. Gal-9 mAb in the same phase of disease diminishes the number of IFN␥-producing cells, reducing disease severity (13) , whereas in vivo knockout of Gal-9 results in the exacerbation of myelin oligodendrocyte glycoprotein (MOG) -driven EAE (13) . In the same model, recent data demonstrated that mice lacking Bat3 develop a less severe form of EAE than wild-type controls on active immunization with MOG (18) . Even more recently, the prevention of Tim-3 signaling in CD4 ϩ T cells-induced EAE was shown to alter the CNS inflammatory pattern due to a differential effect on T h 1 vs. T h 17 cells, whereas preventing Tim-3 signaling in CD8 ϩ T-cell-mediated EAE exacerbated disease (24) . Apoptosis of myelin basic protein (MBP)-specific T lymphocytes was suggested to be a protective mechanism against the progression of MS (25) (26) . Because the Tim-3/Gal-9 interaction stimulates the apoptosis of antigen-specific T h 1 cells and Bat3 protects such cells from Gal-9-mediated cell death, we thought it interesting to analyze the possible role of these molecules and pathways in patients with different forms of MS.
MATERIALS AND METHODS

Patients and control participants
Eighty-seven patients affected by MS as diagnosed by clinical and laboratory parameters and followed by the Centro Sclerosi Multipla of the Don Gnocchi Foundation (Milan, Italy) were included in the study. Stable disease was diagnosed in 30 patients with relapsing-remitting MS (RRMS; median age 40 yr; range 20 -59 yr; 19 females and 11 males) on the basis of brain and spinal cord magnetic resonance imaging (MRI), with gadolinium showing no areas of enhancement at the time of enrollment. Median disease duration was 7 yr (range 1-29 yr); the median Kurtze Expanded Disability Status Scale (EDSS) score was 1.5 (range 1-6). Twenty-four patients (median age 49 yr; range 32-67 yr; 12 females and 12 males) were diagnosed as being affected by primary progressive MS (PPMS) on the basis of the clinical history and of brain and spinal cord MRI with gadolinium that evidenced a stability of the lesion load at the time of enrollment. Median disease duration was 20 yr (range 6 -35 yr); the median EDSS was 6.5 (range 4.5-8). Finally, 33 patients (median age 45 yr; range 36 -61 yr; 22 females and 11 males) were affected by benign MS (BEMS) as confirmed by brain and spinal cord MRI with gadolinium; MRI showed stability or, in many cases, an improvement of the lesion load at the time of enrollment. BEMS was determined to be present based on the most widely accepted definition, i.e., an EDSS score Յ 3.0 (meaning that the patient is fully ambulatory but may have moderate disability in one functional system or mild disability in up to 4 functional systems) after Ն15 yr from the clinical onset of disease. Median disease duration was 21 yr (range 15-30 yr); median EDSS score was 2 (range 0 -3). None of the patients had received immunosuppressive drugs in the year prior to the study period; all of them gave informed consent, according to a protocol approved by the local ethics committee of the Don Gnocchi Foundation. Finally, a group of 40 sex-and age-matched HC participants (median age 48 yr; range 33-62; 27 females and 13 males) was enrolled in the study.
Blood sample collection and cell separation
Whole blood (30 ml) was collected in Vacutainer tubes containing EDTA (Becton Dickinson & Co., Rutherford, NJ, USA). Peripheral blood mononuclear cells (PBMCs) were separated on lymphocyte separation medium (Organon Teknika Corp., Durham, NC, USA) and washed twice in PBS. Leukocytes viability was determined using a Scepter Handheld Automated Cell Counter (Millipore, Boston, MA, USA).
Stimulation of PBMCs for flow cytometry analysis
PBMCs resuspended at 1 ϫ 10 6 cells/ml were stimulated with nonimmunogenic peptides (27) or with a pool of antigenic MBP peptides (10 g/ml; ref. 27 ) ϩ anti-CD28 mAb (1 g/ml; clone 37407.111; R&D Systems, Minneapolis, MN, USA) to facilitate costimulation, at 37°C in a humidified 5% CO 2 atmosphere for 24 h. For cytokine analyses, brefeldin A (10 g/ml; Sigma-Aldrich, St. Louis, MO, USA) was added to the cell cultures during the last 6 h of stimulation to block protein secretion.
Immunofluorescent staining
PBMCs were stained with CD4-, CD8-, CD14-, and Tim-3-specific mAbs for 30 min at room temperature in the dark. For the analysis of cytokine-secreting or intracellular proteinexpressing cells, PBMCs were washed and fixed (Fix and Perm cell permeabilization kits; Caltag Laboratories, Burlingame, CA, USA) for 15 min at room temperature in the dark. Cells were then washed and resuspended in permeabilization reagent (Fix and Perm kits) with Bat3-, Gal-9-, TNF-␣-, IFN␥-, or IL17A-specific mAbs. After incubation, cells were washed and fixed in 1% paraformaldehyde in PBS.
Evaluation of apoptosis
PBMCs were stained with CD4-, CD8-, and Tim-3-specific mAbs for 30 min at 4°C in the dark. For the apoptosis assay, PBMCs were then washed and resuspended in ice-cold 1ϫ binding buffer (Beckman-Coulter, Fullerton, CA, USA) plus 10 l of annexin V (AV) and 20 l of 7-AAD viability dye for 15 min on ice in the dark. Finally, cell suspensions were resuspended in 400 l of 1ϫ binding buffer and analyzed by flow cytometry. Notably, the use of 7-AAD, a DNA-specific viability dye, allows early apoptotic cells to be distinguished from late-apoptotic and necrotic cells. To this goal, a gate capable of distinguishing early apoptosis events (AV ϩhigh and 7 AAD ϩlow ) was selected.
Blocking assay
Purified anti-human Gal-9 (mouse IgG1 k, clone 9M1-3; Biolegend, San Diego, CA, USA) or anti-Tim-3 (mouse IgG1 k, , clone F38-2E2; Biolegend) mAbs were added (10 g/ml) to cell cultures together with the MBP peptide pool and left throughout the stimulation period. Mouse IgG1 isotype control antibodies were used in MBP-stimulated cell cultures.
mAbs
The following mAbs were used in this study: phycoerythrin ( Finally, anti-Bat3 (clone 2B21; mouse IgM k ; Abnova Taipei, Taiwan) was conjugated using the Lightning-Link R-PE conjugation kit (Innova Biosciences, Cambridge, UK).
Cytometric analysis
Analyses were performed using a Beckman-Coulter Gallios flow cytometer equipped with two lasers operating at 488 and 638 nm, respectively, interfaced with Gallios software and analyzed with Kaluza v 1.2; 200,000 events were acquired and gated on forward-and side-scatter properties for lymphocytes or monocytes. Data were collected using linear amplifiers for forward and side scatter and logarithmic amplifiers for FL1-FL6. Samples were first run using isotype control or single fluorochrome-stained preparations for color compensation. Rainbow calibration particles (Spherotec, Lake Forest, IL, USA) were used to standardize results.
Statistical analysis
Quantitative data were not normally distributed (ShapiroWilk test) and are thus summarized as median and interquartile range (25th and 75th percentiles). Comparisons between groups were analyzed to evaluate immunological differences. Kruskal-Wallis ANOVA was performed for each variable.
Comparisons among the different groups were made using a 2-tailed Mann-Whitney U test performed for independent samples. Data analysis was performed using the MedCalc statistical package (MedCalc Software bvba, Mariakerke, Belgium).
RESULTS
MBP-stimulated CD4
؉ , CD8 ؉ , and CD14 ؉ cells expressing Tim-3
Tim-3-expressing immune cells were analyzed in MBPstimulated and in control peptide-stimulated PBMCs of all patients and HC participants by flow cytometry. Whereas no differences were detected when cells were incubated with the pool of control, nonantigenic peptides (Fig. 1) ϩ /Tim-3 ϩ cells were also significantly increased in patients with BEMS and RRMS compared with both patients with PPMS (Pϭ0.0003 and Pϭ0.01, respectively) and HC participants (Pϭ0.0003 for both). Finally, Tim-3-expressing CD14 ϩ cells were comparable in all the groups analyzed ( Fig. 1) .
Results obtained on analyzing mean fluorescence intensity (MFI) showed that Tim-3 MFI was significantly augmented, as well, in CD4 ϩ and CD8 ϩ T cells of patients with BEMS, with the lowest values seen in lymphocytes of patients with PPMS (Fig. 2) .
Gal-9 in MBP-stimulated CD4
؉ , CD8 ؉ , and CD14 ؉ Similar percentages of Gal-9 ϩ cells were seen in all the groups analyzed on incubation with control peptides (Fig. 3) ; nevertheless, significant differences emerged in MBP-stimulated cells. Thus, CD4
ϩ /Gal-9 ϩ T lymphocytes were augmented in the BEMS, RRMS, and HC groups compared to the PPMS group (Pϭ0.008, 0.03, and 0.01, respectively). Also, in this case, the lowest quantities of CD4 ϩ /Gal-9 ϩ T lymphocytes in MBPstimulated cell cultures were seen in cells of patients with a diagnosis of PPMS. Similar trends, that nevertheless did not reach statistical significance, were observed in MBP-stimulated CD8 ϩ and CD14 ϩ cells (Fig. 3) .
MBP-stimulated apoptotic CD4 ؉ and CD8 ؉ T lymphocytes
The interaction between Tim-3 and Gal-9 results in the apoptosis of antigen-specific T h 1 lymphocytes. Apoptosis of cells incubated with either MBP or the control peptides was evaluated next by analyzing CD4 ϩ and CD8 ϩ T lymphocytes that coexpress Tim-3 and AV in patients with MS and HC participants. Results indicated that, whereas once again no differences were seen when cells were incubated with the control peptides, MBP-stimulated CD4 ϩ /Tim-3 ϩ /AV ϩ (apoptotic) T lymphocytes were significantly increased in the BEMS, RRMS, and HC groups compared to patients with PPMS (Pϭ0.02, 0.02, and 0.005, respectively), in whom the lowest amounts of apoptotic CD4 ϩ T lymphocytes were detected (Fig. 4C) .
ϩ lymphocytes were marginally increased in patients with BEMS, as well, but the differences were not significant (Fig. 4D) .
Analyses performed adding a fourth marker (IFN␥ or IL-17) showed that even if higher quantities of MBPstimulated CD4 ϩ /Tim-3
ϩ T lymphocytes were seen in patients with BEMS, the differences were not significant (data not shown).
Incubation of cell cultures prior to MBP stimulation with either Tim-3-or Gal-9-specific blocking mAbs reduced the percentage of CD4 ϩ /AV ϩ and CD8 ϩ /AV ϩ T lymphocytes in all the groups analyzed, with the exception of patients with PPMS, in whom apoptotic cells were instead increased on incubation with both antibodies (Fig. 4E, F) . These results confirm that the interaction between Tim-3 and Gal-9 induces apoptosis of antigen-specific lymphocytes and indicate that this pathway is not defective per se in MS, with the exception of what occurs in patients affected by the particularly severe progressive form of disease (PPMS). 
Bat3-expressing CD4
؉ and CD8
؉ T cells in MBP-stimulated PBMCs
Binding of the molecular adaptor Bat3 to the intracellular tail of Tim-3 protects lymphocytes from Tim-3/ Gal-9-mediated cell death and stimulates the preferential production of IFN␥ by T h 1 cells. Bat3 intracellular expression was analyzed next in control peptides and in MBP-stimulated cells of all the individuals enrolled in the study. The lowest percentage of Bat3-expressing CD4 ϩ T lymphocytes was seen in patients with BEMS, whereas the highest amount of CD4 ϩ /Bat3 ϩ cells was observed in patients with PPMS. The increase seen in patients with PPMS was significant compared with the results obtained in all the other groups (Pϭ0.003 vs. BEMS; Pϭ0.001 vs. RRMS, Pϭ0.02 vs. HC). Notably, similar results were observed when CD8 ϩ Bat3 ϩ cells were analyzed, as these cells were statistically augmented in patients with PPMS compared to the RRMS and HC groups (Pϭ0.02 in both cases; Fig. 5E, F) . Also, in this case, no differences were detected when PBMCs were incubated with control peptides (Fig. 5) .
IFN␥-and IL-17-expressing T lymphocytes: effect of Tim-3-and Gal-9-blocking antibodies
IFN␥-and IL-17-producing CD4
ϩ and CD8 ϩ T lymphocytes were analyzed in MBP-stimulated cultures after incubation with Tim-3-or Gal-9-blocking mAbs. In both cases, incubation resulted in increased percentages of MBP-stimulated CD4 ϩ /IFN␥ ϩ and CD8 ϩ /IFN␥ ϩ T lymphocytes in the BEMS, RRMS, and HC groups, whereas these cells were reduced in the PPMS groups (Fig. 6A) . Similar results were obtained when IL-17-producing cells were analyzed. Thus, incubation with Tim-3-or Gal-9-blocking antibodies augmented MBPstimulated CD4 ϩ /IL-17 ϩ and CD8 ϩ /IL-17 ϩ lymphocytes in all groups of individuals, with the exception of patients with PPMS, in whom these cells were instead reduced (Fig. 6B) .
Because Tim-3-and Gal-9-blocking antibodies impede the reciprocal ligation of these receptors, thus reducing apoptosis, and, as indicated above, in vitro apoptosis is down-modulated by incubation of cells with these antibodies in the BEMS, RRMS, and HC groups but not in patients with PPMS, the increased percentage of IFN␥ and IL-17-expressing T lymphocytes seen in the BEMS, RRMS, and HC groups is likely to be the consequence of a reduced apoptosis rate.
DISCUSSION
Binding of Tim-3 to Gal-9 induces the apoptosis of antigen-specific cells; this process is reduced by the ligation of Bat3 to the intracellular tail of Tim-3 (5,  11-15, 18, 19) . Because MBP-specific T lymphocytes are suggested to play a direct pathogenic role in MS, and their apoptosis was observed to be associated with reduced or absent rates of disease progression (25) (26) , we analyzed the possible involvement of the Tim-3/Gal-9/Bat3 pathway in patients with different MS phenotypes. Results indicated that increased Tim-3 and Gal-9 expression is seen in individuals with a diagnosis of BEMS, resulting in an augmented death rate of MBPspecific CD4 ϩ T lymphocytes. This was confirmed by the observation that Bat3-expressing cells are reduced in these same individuals. Because Bat3 impedes the Tim-3/Gal-9-mediated apoptosis (18, 19) , its reduction in BEMS offers an additional justification for the increased susceptibility to apoptosis of MBP-specific cells seen in these patients. Notably, the situation observed in PPMS, a particularly aggressive form that results in rapid disease progression, was drastically different. Thus, in these individuals, a reduced quantity of Tim-3 ϩ and Gal-9 ϩ T lymphocytes, as well as an increased amount of Bat3-expressing cells, was associated with a significantly reduced rate of apoptosis of MBPspecific cells.
It could be argued that the frequencies of cells expressing Tim-3, Gal-9, and Bat3 are extremely low; it is, nevertheless, important to underline that what are shown herein are the frequencies of MBP-stimulated cells. We are, thus, specifically considering and analyzing only those antigen-specific cells that are suspected to drive the disease. In the light of this consideration of the realization that the percentage of lymphocytes for any specific antigen in peripheral blood is below detection, and of the literature showing how, in other diseases, the analysis of apparently minuscule quantities of antigen-specific cells correlates with clinical endpoints (28), this critique is not justified.
Circulating autoreactive T cells that attack and damage self-antigens in autoimmune diseases originate from alterations in the complex mechanisms of clonal deletion taking place during central tolerance (29) . These cells also manage to elude peripheral tolerance mechanisms, including induction of anergy and/ or apoptosis (30) . If both control mechanisms are avoided, self-reactive T cells are activated, and autoimmune responses are initiated (31) . In MS, autoreactive T lymphocytes specific for MBP play an important pathogenic role; these cells are activated and clonally expanded in the disease, and they accumulate in the CNS, as well as in peripheral compartments (32-33). Apoptosis of MBP-specific cells was observed to be beneficial in MS by reducing the size of the pool of auto-reactive T lymphocytes (25) (26) . Apoptosis can be mediated by a number of mechanisms, among which the interaction between proteins expressed on cell surface has a prominent importance. We have previously focused on the programmed cell death (PD)1/ PD-L1-mediated cell death and have shown that this pathway is greatly deficient in RRMS during the phases of disease activity (26) . Data herein offer further support to the concept that alterations in the mechanisms that control the apoptotic rate of antigen-specific cells are involved in the pathogenesis of autoimmune conditions. Thus, results indicating that the Tim-3/Gal-9-driven apoptosis of MBP-specific T cells is significantly augmented in patients with a diagnosis of BEMS, a disease phenotype in which lack of apparent disease progression associates with a marginal degree of inflammation, and a MRI-documented stability or improvement of the lesion load suggest a role for this immune pathway in determining disease progression. This hypothesis is further strengthened by the specular results obtained on analyzing this pathway in PPMS, an aggressive form of MS that is at the opposite end of the clinical spectrum of disease manifestation.
Our results confirm previous observations showing the presence of a dysregulation of Tim-3 expression in lymphocytes of patients with MS (20, 22) . Data herein are also the first report of an alteration of Bat3 levels in individuals with MS and lend support to recent results indicating that increased Bat3 expression is associated with the promotion of autoimmunity, possibly as a consequence of its ability to obstacle Tim-3-mediated apoptosis (18) . Finally, results showing that increased amounts of Tim-3 ϩ cells that coexpress AV (apoptotic lymphocytes) were increased in BEMS are in accordance with data obtained both in the EAE model and in patients, indicating that Tim-3-mediated apoptotic signaling is involved in preventing the spread of autoreactive T cells (3-4, 13, 18, 20, 23) .
Experiments in which the Tim-3/Gal-9 interaction was impeded by blocking antibodies resulted in a reduction of apoptotic MBP-specific T lymphocytes in the BEMS, RRMS, and HC groups; these cells were increased instead in patients with PPMS. The use of Tim-3-and Gal-9-blocking antibodies also resulted in an increased percentage of MBP-specific IFN␥-and IL-17-producing cells in all individuals, again with the exception of patients with PPMS. These results confirm that the Tim-3/Gal-9 interaction mediates apoptosis of IFN␥-and IL-17-producing T lymphocytes and indicate that this pathway is altered in PPMS, suggesting a T-cell-intrinsic deregulation of both Tim-3 expression and function in this subset of patients with MS. Notably, results of experiments performed in the mouse model showed that whereas higher concentrations of Gal-9 result in the apoptosis of Tim-3-expressing T h 1 and T h 17 cells, reduced amounts of this protein favor the proliferation of T h 1 lymphocytes (34). This seems to be the situation observed in patients with PPMS, in whom very low amounts of Gal-9 are associated with low apoptotic rates and higher percentages of MBP-specific T h 1 and T h 17 cells.
Comparisons between levels of Tim-3 expression in T h 1 and T h 17 lymphocytes have shown lower levels of Tim-3 expression in T h 17 cells of both mice (10, 16) and humans (1) . These data led to the suggestion that low-level Tim-3 expression may allow escape of T h 17 cells from Gal-9-mediated cell death (17) . The biological consequences of the low Tim-3 expression by T h 17 cells have, nevertheless, not been established. Our results suggest that the levels of Tim-3 and Gal-9 expressed by cells of patients with RRMS and BEMS are sufficient to warrant the functionality of the Tim-3/ Gal-9 pathway. This pathway is malfunctioning in patients with PPMS, probably because of the reduced levels of both proteins observed in cells of these individuals or, alternatively, as a consequence of alterations in their functionality. That functional alterations could be responsible for the reduced rate of apoptosis of MBP-specific cells in patients with PPMS is reinforced by the observation that the expression levels of these proteins are similar in patients with PPMS and HC participants; nevertheless, in HC participants, the percentage of antigen-specific apoptotic lymphocytes is significantly increased.
Dysregulation of Tim-3 expression is not limited to MS, as it has been previously reported both in psoriasis (35) and in RA (36 -37) . In RA, in particular, higher Tim-3 expression was shown to correlate with lower indexes of disease activity, a picture that is very similar to what we observed in stable RRMS and BEMS. Notably, Tim-3 expression on T lymphocytes is up-regulated patients with MS who are treated with either IFN␤ or glatiramer acetate (22) ; similarly, increased Tim-3 expression is described in patients with RA who enter remission after treatment (36) .
Recent evidence in chronic viral infections indicates that expression of Tim-3 marks a population of exhausted T cells (38 -40 
